期刊
PLOS ONE
卷 16, 期 12, 页码 -出版社
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0260958
关键词
-
资金
- Innovationsfonden Denmark [0208-00081, 0153-00209]
- Novo Nordisk Foundation under NFF [NNF20CC0035580]
Niclosamide has been validated as a potent antiviral agent against SARS-CoV-2 in human airway models, demonstrating efficacy against multiple variants. This highlights its potential as a therapeutic agent for COVID-19.
SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 human airway model. Furthermore, niclosamide remains its potency against the D614G, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants. Our data further support the potent anti-SARS-CoV-2 properties of niclosamide and highlights its great potential as a therapeutic agent for COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据